Beta
339471

Impact of Sacubitril–Valsartan Treatment on Diastolic Function and Right Ventricular Function in Patient with Heart Failure with Reduced Ejection Fraction

Article

Last updated: 24 Dec 2024

Subjects

-

Tags

Internal Medicine

Abstract

Background: It was proved that sacubitril-valsartan has a major role in ventricular remodeling resulting in improving ejection fraction and ventricular size. Although evaluating the diastolic function in those presenting with Heart failure and reduced ejection fraction [HFrEF] was neglected, the majority of patients with HFrEF also have diastolic dysfunction.
The Aim of the work: In this study, we will focus on studying and explaining the impact of sacubitril–valsartan on diastolic dysfunction and RVD and explaining if the clinical improvement is attributed to improvement in diastolic function and right-side function.  
Patients and Methods: Our prospective study enrolled 60 HFrEF patients. All of the included patients were submitted for, ECG, and Standard 2D Doppler transthoracic echocardiography. The following parameters were collected; TAPSE [Tricuspid Annular Plane Systolic Excursion], FAC [fractional area change] 3Systolic pulmonary artery pressure [SPAP], Myocardial performance index [M P I].
Results: According to the percentage of improvement among the studied cases, the majority [80%] of class II cases improved and 20% had no change. Similarly, 82.1% of class III patients saw improvement in NYHA classification. Whereas all cases in class IV were improved [100%]. According to the change of systolic and diastolic blood pressure, the mean Systolic Blood Pressure [mmHg] of subjects before therapy with sacubitril–valsartan was 125.88 ±13.7 and it was 108.8± 11.3 of subjects following therapy with sacubitril –valsartan, and this was statistically substantial [P = 0.001]. The mean of Diastolic Blood Pressure [mmHg] of subjects before therapy with sacubitril –valsartan was 85.25 ± 8.9 and it was 74 ± 11.1 of subjects following therapy with sacubitril –valsartan, and this was statistically substantial [P = 0.001].
Conclusion: The measured parameters of right ventricular function such as TAPSE, MPI, and Fractional area change were all improved significantly indicating a positive effect for sacubitril-valsartan on the right ventricular function.

DOI

10.21608/ijma.2024.255322.1889

Keywords

Sacubitril–Valsartan, right ventricular function, Heart failure

Authors

First Name

Alaa

Last Name

Algedily

MiddleName

Khairy

Affiliation

Department of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Email

alaa_201176@yahoo.com

City

Motobus

Orcid

-

First Name

Sami

Last Name

Nouh

MiddleName

Hassan

Affiliation

Department of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Email

samihassan@gmail.com

City

-

Orcid

-

First Name

Mohammed

Last Name

Abdel Samee

MiddleName

Sami

Affiliation

Department of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Email

mohammed345@gmail.com

City

-

Orcid

-

Volume

5

Article Issue

12

Related Issue

45907

Issue Date

2023-12-01

Receive Date

2023-12-13

Publish Date

2023-12-01

Page Start

3,914

Page End

3,922

Print ISSN

2636-4174

Online ISSN

2682-3780

Link

https://ijma.journals.ekb.eg/article_339471.html

Detail API

https://ijma.journals.ekb.eg/service?article_code=339471

Order

339,471

Type

Original Article

Type Code

816

Publication Type

Journal

Publication Title

International Journal of Medical Arts

Publication Link

https://ijma.journals.ekb.eg/

MainTitle

Impact of Sacubitril–Valsartan Treatment on Diastolic Function and Right Ventricular Function in Patient with Heart Failure with Reduced Ejection Fraction

Details

Type

Article

Created At

24 Dec 2024